SUGCT

Across TCGA pan-cancer cohorts, SUGCT mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SUGCT data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SUGCT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SUGCT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where SUGCT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.926	0.625	.003	28	view →
UCEC	DFS	Median	All	0.777	1.000	.015	10	view →
LUAD	DFS	Quartile	III,IV	0.396	0.986	.038	3	view →
LSCC	OS	Median	III,IV	0.488	0.979	.022	2	view →
PDAC	OS	Tertile	All	0.488	0.276	.021	2	view →
HNSC	DFS	Median	III,IV	1.000	0.899	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SUGCT–CCRCC (OS)

Open the CCRCC breakdown →